2020 Avon Court, #4
Charlottesville, VA 22902
434-220-0718
info@diffusionpharma.com
 RSS Feed
  • Home
  • About Us
    • Company History
    • Leadership Team
      • Management Team
        • David Kalergis, JD/MBA
        • John L. Gainer, PhD
        • Matthew W. Hantzmon
        • Ben Shealy, MBA/CFA
        • David R. Jones, M.D.
        • Kim Whitten, PharmD, RAC
        • Robert Murray, PhD
        • James Edward John, III
        • Kelly Hoy
        • Jenny Tornqvist, Ph.D.
        • Tracey Linkous Danner, CTM
      • Board of Directors
        • David Kalergis, JD/MBA
        • John L. Gainer, PhD
        • Mark T. Giles, JD
        • Thomas Byrne, JD
        • Robert W. Adams, JD
      • Scientific Advisory Board
        • John L. Gainer, PhD
        • Stuart A. Grossman, MD
        • John A. Jane, Sr., MD, Ph.D., FRCS(C), FACS
        • David R. Jones, M.D.
        • Guy M. Chisolm, Ph.D.
    • Patent Portfolio
    • News
      • Press Releases
      • Subscribe to our news
      • Key Contacts
    • Contact Us
    • Directions
  • Business Development
  • Investors
  • Pipeline
    • Patient Populations
    • Clinical Development of TSC
  • Science
    • Hypoxia and Hypoxic Conditions
    • Published Research
    • Our Scientific Collaborators

Ben Shealy, MBA/CFA

Chief Financial Officer, Treasurer

Ben Shealy has over twenty years of experience in financial management and private and public corporate financings. As CFO of the Company, Mr. Shealy has responsibility for implementing the Company’s overall financial strategy and directing the performance of day-to-day operational finance matters. Prior to joining Diffusion Pharmaceuticals, he was Vice President of Finance at Corporate Software where he directed M&A activities which involved overseeing the firm’s $100+ million investment in several start-up high technology companies, and the sale of Corporate Software to Level 3 Communications. Mr. Shealy also was responsible for Corporate Software’s financial planning and analysis functions and the corporate budgeting activity ($1.2 billion of world-wide sales). Mr. Shealy’s Wall Street background encompassed both the sell-side (Donaldson, Lufkin & Jenrette and Prudential Securities) and the buy-side (John Hancock). Mr. Shealy received a BS in Accounting from San Jose State University, an MBA in Finance from Columbia University in New York City, and is a CFA Charter holder.



Home | About Us | Business Development | Investors | Pipeline | Science


BioNetwork East - Investment Challenge Winner

©2010 Diffusion Pharmaceuticals LLC
Terms of Use